Fairmount Funds Management LLC sold $300.0M of Oruka Therapeutics (ORKA)

Executed Jul 1, disclosed Jul 2, the same day.

Value, as filed

$300.0M

3,553,410 sh × $84.43

Executed

Jul 1

the trade date, as filed

Disclosed

Jul 2

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

FL Fairmount Funds Management LLC Director profile →

Fairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.

The name

ORKA

Oruka Therapeutics, Inc. ORKA · Healthcare · 27 filings in 24 months ticker →

Healthcare · Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psor…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→